WO2023230220A3 - Methods and compositions for treating cancer - Google Patents

Methods and compositions for treating cancer Download PDF

Info

Publication number
WO2023230220A3
WO2023230220A3 PCT/US2023/023510 US2023023510W WO2023230220A3 WO 2023230220 A3 WO2023230220 A3 WO 2023230220A3 US 2023023510 W US2023023510 W US 2023023510W WO 2023230220 A3 WO2023230220 A3 WO 2023230220A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
treating cancer
immune checkpoint
checkpoint inhibitor
Prior art date
Application number
PCT/US2023/023510
Other languages
French (fr)
Other versions
WO2023230220A2 (en
Inventor
Steven M. Fruchtman
Matthew PARRIS
Stephen C. Cosenza
Original Assignee
Onconova Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onconova Therapeutics, Inc. filed Critical Onconova Therapeutics, Inc.
Publication of WO2023230220A2 publication Critical patent/WO2023230220A2/en
Publication of WO2023230220A3 publication Critical patent/WO2023230220A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Disclosed herein is a method of treating a cancer by administering 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile and an immune checkpoint inhibitor. In some embodiments, the immune checkpoint inhibitor is an anti-PD-1 antibody or an anti-CTLA4 antibody. Also disclosed herein are combinations of 8-cyclopentyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile and an immune checkpoint inhibitor.
PCT/US2023/023510 2022-05-25 2023-05-25 Methods and compositions for treating cancer WO2023230220A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263345539P 2022-05-25 2022-05-25
US63/345,539 2022-05-25

Publications (2)

Publication Number Publication Date
WO2023230220A2 WO2023230220A2 (en) 2023-11-30
WO2023230220A3 true WO2023230220A3 (en) 2024-03-21

Family

ID=88919902

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/023510 WO2023230220A2 (en) 2022-05-25 2023-05-25 Methods and compositions for treating cancer

Country Status (1)

Country Link
WO (1) WO2023230220A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170290808A1 (en) * 2016-04-07 2017-10-12 Chemocentryx, Inc. Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
US20220002293A1 (en) * 2018-11-12 2022-01-06 Onconova Therapeutics, Inc. 8-cyclopentyl-7-oxo-2-(4-piperazin-1-yl-phenylamino)-7, 8-dihydro-pyrido [2,3-d]pyrimidine-6-carbonitrile and uses thereof in treating proliferative disorders
WO2023091724A1 (en) * 2021-11-18 2023-05-25 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
WO2023092104A1 (en) * 2021-11-18 2023-05-25 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170290808A1 (en) * 2016-04-07 2017-10-12 Chemocentryx, Inc. Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
US20220002293A1 (en) * 2018-11-12 2022-01-06 Onconova Therapeutics, Inc. 8-cyclopentyl-7-oxo-2-(4-piperazin-1-yl-phenylamino)-7, 8-dihydro-pyrido [2,3-d]pyrimidine-6-carbonitrile and uses thereof in treating proliferative disorders
WO2023091724A1 (en) * 2021-11-18 2023-05-25 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
WO2023092104A1 (en) * 2021-11-18 2023-05-25 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE PUBCHEM SUBSTANCE 2 February 2015 (2015-02-02), ANONYMOUSA: "WDHAAJIGSXNPFO-UHFFFAOYSA-N", XP093152632, Database accession no. 225134244 *

Also Published As

Publication number Publication date
WO2023230220A2 (en) 2023-11-30

Similar Documents

Publication Publication Date Title
SA520420524B1 (en) Tetrahydro-Imidazo[4,5-C]Pyridine Derivatives as Pd-L1 Immunomodulators
DK0725790T3 (en) Substituted tetra and pentapeptide inhibitors of protein farnesyl transferase
AU6422399A (en) 6-substituted pyrazolo(3,4-d)pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
AU2001231763A1 (en) Dosing regimen
CR20220537A (en) [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS
WO2003101444A8 (en) Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
MY140748A (en) Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
DK0677039T3 (en) Cyclobutane derivatives such as squalene synthetase and protein farnesyl transferase inhibitors
EP2494965A3 (en) Vitamin K for Prevention and Treatment of Skin Rash Secondary to Anti-EGFR Therapy
MX2022003005A (en) Anti-cd39 antibody compositions and methods.
BR112021023607A2 (en) Pyrrolo[2,3-b]pyridine and pyrazolo[3,4-b]pyridine derivatives substituted by protein kinase inhibitors
AU2003256203A1 (en) Alpha-7 nicotinic receptor agonists and statins in combination
MX2020012613A (en) Compositions and uses thereof for treating disease or condition.
MX2022005157A (en) Harnessing the power of microbiota and metabolites for the treatment of cancer.
WO2023230220A3 (en) Methods and compositions for treating cancer
MXPA03007413A (en) Composition and method for treating inflammatory disorders.
SG153661A1 (en) Formulation and methods for the treatment of thrombocythemia
AU2001243657A1 (en) Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor
EP4104855A4 (en) Use of anti-pd-1 antibody in treating neuroendocrine tumors
MX2022000794A (en) 4-(imidazo[1,2-a]pyridin-3-yl) -pyrimidine derivatives.
MX2023014015A (en) Amino acid hydration formulation and method of use.
MX2023002288A (en) Protein secretion inhibitors.
WO2023230286A3 (en) Methods and compositions for treating cancer
MX2021013083A (en) Derivatives of glycero-manno-heptose phosphate and their use in modulating an immune response.
EP4342543A3 (en) Tert-butyl (s)-2-(4-(phenyl)-6h-thieno[3,2-f][1,2,4]triazolo[4,3-a] [1,4]diazepin-6-yl) acetate derivatives and related compounds as bromodomain brd4 inhibitors for treating cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23812557

Country of ref document: EP

Kind code of ref document: A2